Achieve Life Sciences, Inc. ACHV
We take great care to ensure that the data presented and summarized in this overview for ACHIEVE LIFE SCIENCES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ACHV
Top Purchases
Top Sells
About ACHV
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Insider Transactions at ACHV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 16
2024
|
Jerry Wan Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,857
+18.41%
|
$8,571
$3.67 P/Share
|
|
Aug 16
2024
|
John Bencich CEO |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+4.73%
|
$15,000
$3.67 P/Share
|
|
Aug 16
2024
|
Cindy Jacobs President & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
2,660
+7.41%
|
$7,980
$3.67 P/Share
|
|
Apr 19
2024
|
Cindy Jacobs President & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,957
-11.47%
|
$15,828
$4.51 P/Share
|
|
Apr 19
2024
|
Cindy Jacobs President & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,250
+32.01%
|
-
|
|
Apr 19
2024
|
Jerry Wan Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,250
-18.66%
|
$9,000
$4.51 P/Share
|
|
Apr 19
2024
|
Jerry Wan Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,625
+31.81%
|
-
|
|
Apr 19
2024
|
Richard Alistair Stewart Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
10,125
-16.6%
|
$40,500
$4.51 P/Share
|
|
Apr 19
2024
|
Richard Alistair Stewart Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+26.95%
|
-
|
|
Apr 19
2024
|
John Bencich CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,088
-5.98%
|
$24,352
$4.51 P/Share
|
|
Apr 19
2024
|
John Bencich CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+19.73%
|
-
|
|
Mar 04
2024
|
Richard Alistair Stewart Executive Chairman |
BUY
Open market or private purchase
|
Direct |
10,000
+20.62%
|
$40,000
$4.58 P/Share
|
|
Mar 04
2024
|
John Bencich CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+11.53%
|
$40,000
$4.58 P/Share
|
|
May 30
2023
|
John Bencich CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+6.97%
|
$25,000
$5.5 P/Share
|
|
Apr 28
2023
|
Jerry Wan Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
669
-9.42%
|
$5,352
$8.29 P/Share
|
|
Apr 28
2023
|
Jerry Wan Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+14.97%
|
-
|
|
Apr 28
2023
|
Richard Alistair Stewart Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
2,250
-7.32%
|
$18,000
$8.29 P/Share
|
|
Apr 28
2023
|
Richard Alistair Stewart Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+13.99%
|
-
|
|
Apr 28
2023
|
John Bencich CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,827
-2.87%
|
$14,616
$8.29 P/Share
|
|
Apr 28
2023
|
John Bencich CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+10.55%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 10.5K shares |
|---|---|
| Exercise of conversion of derivative security | 69.4K shares |
| Open market or private purchase | 20K shares |
| Payment of exercise price or tax liability | 22.4K shares |
|---|